These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16208125)

  • 1. Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment.
    Aladag M; Camci C; Huang Y; Wright H; Rizvi S; Gurakar A; Stokes K; Sebastian A
    J Clin Gastroenterol; 2005; 39(10):923-4. PubMed ID: 16208125
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
    Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
    Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients.
    Mostafa AM; Saafan HA; Al-Tawashi AS; Kasem MH; Alaa AM; Eltobgy MM; Moubarak AS; Gharib MM; Awwad MA; Omar HM; El-Derany MO
    Virus Res; 2021 Jan; 292():198226. PubMed ID: 33171166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin 2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon-alpha 2b and ribavirin.
    Henke H; Schmiegel W; Brechmann T; Voigt E; Griga T
    J Clin Gastroenterol; 2004 Mar; 38(3):301-3. PubMed ID: 15128086
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients.
    Carrat F; Bedossa P; Lunel-Fabiani F; Morand P; Pialoux G; Piroth L; Salmon-Céron D; Bani-Sadr F; Perronne C; Cacoub P; Pol S
    AIDS; 2008 Jul; 22(12):1513-5. PubMed ID: 18614875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiviral treatments during cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2006; 30(6-7):899-902. PubMed ID: 16885876
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of interferon-alpha for chronic hepatitis C.
    Moriyama M; Arakawa Y
    Expert Opin Pharmacother; 2006 Jun; 7(9):1163-79. PubMed ID: 16732703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.
    Pinzone MR; Zanghì AM; Rapisarda L; D'Agata V; Benanti F; Spartà D; Nunnari G; Cacopardo B
    Eur Rev Med Pharmacol Sci; 2014 Dec; 18(2 Suppl):11-5. PubMed ID: 25535185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summaries for patients. Sustained virologic response in hepatitis C.
    Ann Intern Med; 2007 Nov; 147(10):I47. PubMed ID: 18025441
    [No Abstract]   [Full Text] [Related]  

  • 13. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
    Takayama K; Furusyo N; Ogawa E; Ikezaki H; Shimizu M; Murata M; Hayashi J
    World J Gastroenterol; 2015 Apr; 21(15):4696-706. PubMed ID: 25914481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
    Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
    Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of chronic hepatitis C in southern Taiwan.
    Chuang WL; Yu ML; Dai CY; Chang WY
    Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lipid profile and chronic hepatitis C virus.
    Purnak T; Efe C; Beyazit Y; Ozaslan E
    Hepatology; 2011 Feb; 53(2):716-7. PubMed ID: 20890943
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chronic C virus infection management].
    García González N; Prieto Valtueña J
    Rev Clin Esp; 2003 Sep; 203(9):443-4. PubMed ID: 14563259
    [No Abstract]   [Full Text] [Related]  

  • 18. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
    Wedemeyer H; Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
    [No Abstract]   [Full Text] [Related]  

  • 19. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Martínez-Bauer E; Forns X
    Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.